La catena delle opzioni mostra i dati chiave delle opzioni azionarie di CervoMed a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per CervoMed..

CervoMed (NASDAQ:CRVO) Azioni, Catena delle Opzioni

CervoMed

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

CervoMed Inc

News

Politics

General

2024 Presidential Election Polls Close In The Following States: GA, IN, KY, SC, VA, VT

Seaport Global analyst Tom Curran initiates coverage on First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Neutral rating.

Initiation

Analyst Ratings

FSLR

Seaport Global Initiates Coverage On First Solar with Neutral Rating

Scotiabank analyst Greg Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $480 to $486.

Price Target

VRTX

Scotiabank Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $486

Scotiabank analyst Greg Harrison maintains Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) with a Sector Outperform and raises the price target from $62 to $70.

IRON

Scotiabank Maintains Sector Outperform on Disc Medicine, Raises Price Target to $70

Scotiabank analyst Mario Saric maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Sector Outperform and raises the price target from $55.5 to $59.5.

Scotiabank Maintains Sector Outperform on Brookfield Asset Mgmt, Raises Price Target to $59.5

Scotiabank analyst Andres Coello maintains TIM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIMB#NYSE">TIMB</a>) with a Sector Outperform and lowers the price target from $24.8 to $23.2.

TIMB

Scotiabank Maintains Sector Outperform on TIM, Lowers Price Target to $23.2

Scotiabank analyst Maher Yaghi maintains BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) with a Sector Perform and lowers the price target from C$50.5 to C$47.5.

TSX:BCE

Scotiabank Maintains Sector Perform on BCE, Lowers Price Target to C$47.5

Citigroup analyst Christopher Danely maintains GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral and lowers the price target from $45 to $40.

Citigroup Maintains Neutral on GLOBALFOUNDRIES, Lowers Price Target to $40

NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) passed Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) to become the world's largest publicly traded <a href="https://www.benzinga.com/news/24/11/41751557/nvidia-takes-short-lived-lead-over-apple-in-valuation">company on Tuesday. </a>
The Details: Nvidia ended Tuesday's trading session with a market capitalization of $3.43 trillion, slightly <a href="https://www.benzinga.com/news/24/11/41751557/nvidia-takes-short-lived-lead-over-apple-in-valuation">edging out </a>Apple&#8217;s $3.38 trillion valuation, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>. The semiconductor giant's dominance in the artificial intelligence chip market has fueled its exponential growth of more than 200% over the past year.&nbsp;
Read More: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/11/41724410/nvidia-joining-dow-jones-industrial-average-where-tech-giant-ranks-in-the-index-why-sh">Nvidia Joining Dow Jones Industrial Average: Where Tech Giant Ranks In The Index, Why Sherwin-Williams Addition Could Be More Important</a>
Nvidia briefly passed Apple <a href="https://www.benzinga.com/news/24/06/39386946/microsoft-apple-step-aside-nvidia-is-now-the-most-valuable-public-company-in-the-world">in market cap </a>in June before sliding over the summer.<a href="https://www.cnbc.com/quotes/MSFT/"> </a>Nvidia&#8217;s ascent to the top highlights the growing importance of AI technology and the pivotal role that Nvidia's specialized hardware plays in its development.&nbsp;
Despite Nvidia's remarkable growth over the past year, analysts remain bullish on the company's growth ahead. The three most recent analyst ratings were released by BofA Securities, Goldman Sachs and Morgan Stanley in October with an average price target of $163.33 between the three. There&#8217;s an implied 17.04% upside for Nvidia stock from these analyst ratings.
Last Friday, S&amp;P Dow Jones announced that Nvidia <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/11/41724410/nvidia-joining-dow-jones-industrial-average-where-tech-giant-ranks-in-the-index-why-sh">is joining the Dow Jones Industrial Average on Nov. 8 </a>replacing Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and joining Apple in the blue-chip index. 
NVDA Price Action: According to data from Benzinga Pro, Nvidia shares ended Tuesday's session 2.84% higher at $139.91.&nbsp;
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41690154/shock-october-jobs-report-leaves-fed-in-tight-spot-experts-say-interest-rate-cuts-a">Shock October Jobs Report Leaves Fed In &#8216;Tight Spot:&#8217; Experts Say Interest Rate Cuts Ahead</a></li>
</ul>
Image: Shutterstock

Large Cap

Movers

Tech

AAPL

INTC

NVDA

Nvidia Blows Past Apple To Become World's Most Valuable Company

Lake Street analyst Mark Argento maintains Gaia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) with a Buy and raises the price target from $6 to $7.

GAIA

Lake Street Maintains Buy on Gaia, Raises Price Target to $7

Lake Street analyst Thomas Flaten maintains Castle Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>) with a Buy and raises the price target from $34 to $40.

CSTL

Lake Street Maintains Buy on Castle Biosciences, Raises Price Target to $40

Lake Street analyst Jaeson Schmidt maintains NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) with a Buy and lowers the price target from $60 to $41.

NSSC

Lake Street Maintains Buy on NAPCO Security Techs, Lowers Price Target to $41

Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) .

Guidance

GIFI

Gulf Island Fabrication expect FY2024 adjusted consolidated EBITDA of $11M-$13M.

Lake Street analyst Eric Martinuzzi maintains QuinStreet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNST#NASDAQ">QNST</a>) with a Hold and raises the price target from $20 to $25.

QNST

Lake Street Maintains Hold on QuinStreet, Raises Price Target to $25

Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) .

SNDX

Syndax Pharmaceuticals FY2024 R&D expenses forecast: $245M-$250M.

Loop Capital analyst Rob Sanderson maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Buy and raises the price target from $14 to $16.

SNAP

Loop Capital Maintains Buy on Snap, Raises Price Target to $16

Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) .

GPOR

Gulfport Energy Full Year 2024: Drilling and completion capex guidance cut to $325M-$335M.

Loop Capital analyst Garik Shmois maintains Knife River Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNF#NYSE">KNF</a>) with a Buy and lowers the price target from $105 to $100.

Loop Capital Maintains Buy on Knife River Holding, Lowers Price Target to $100

Barclays analyst Blayne Curtis maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Overweight and lowers the price target from $330 to $280.

NXPI

Barclays Maintains Overweight on NXP Semiconductors, Lowers Price Target to $280

It's Election day! Voters are visiting polling locations and social media mavens are sharing opinions and local reports in megathreads, polls and comments on Reddit Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>).
Here are some notable threads to follow for election <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41631795/reddit-remains-a-favorite-for-wall-street-after-emphatic-beat-and-raise-in-q3">coverage on Reddit.&nbsp;</a>
Polls Open: Subreddit r/politics has over 8.5 million subscribers and features a <a href="https://www.reddit.com/r/politics/comments/1gkefi6/rpolitics_2024_us_elections_live_thread_part_59/">live thread</a> with 59 parts titled, "2024 US Elections Live Thread, Part 59" which contains more than 3,200 comments, voter turnout reports from different locations and live commentary on election developments.&nbsp;
Subreddit r/moderatepolitics has 295,000 members and a <a href="https://www.reddit.com/r/moderatepolitics/">poll titled</a> "Who are you voting for in the 2024 US Presidential Election." At the time of publication, 2,100 Redditors selected Harris, 1,300 selected Trump, 301 selected Other and 842 responded with Not Voting.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/earnings/24/10/41612293/reddit-stock-soars-after-strong-q3-results-q4-guidance-above-estimates-dauqs-grow-17-and-more">Reddit Stock Soars After Strong Q3 Results, Q4 Guidance Above Estimates: DAUq&#8217;s Grow 17% And More</a>
Reddit also features local subreddits like r/Pennsylvania, which has <a href="https://www.reddit.com/r/Pennsylvania/comments/1gjutyd/the_election_day_mega_thread/">a thread</a> titled, "The Election Day Mega Thread" where users can find coverage of the crucial swing state and voting guides and polling locations. The thread also provides local polling updates and news with first-hand accounts from voters across the state.&nbsp;
Where To Find Results: FiveThirtyEight, the data journalism outlet, will feature county-by-county data breakdowns as the polling results come in at its r/fivethirtyeight <a href="https://www.reddit.com/r/fivethirtyeight/">subreddit</a>. It also features discussions about polling accuracy and several live election megathreads.&nbsp;&nbsp;
The r/Journalism <a href="https://www.reddit.com/r/Journalism/">subreddit</a> will provide authoritative sources for results, including updates from the Associated Press and major networks, as well as discussions about result reporting methodology.&nbsp;
Reddit&#8217;s election coverage offers a blend of real-time updates and community engagement across various specialized subreddits, though most users recommend keeping multiple sources open for the most complete picture.&nbsp;
RDDT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Reddit shares ended Tuesday&#8217;s session 12.42% higher at $122.57.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41685913/jpmorgan-to-pay-investors-151-million-after-sec-flags-various-law-violations">JPMorgan To Pay Investors $151 Million After SEC Flags &#8216;Various Law Violations&#8217;</a></li>
</ul>
Photo: Shutterstock

Social Media

RDDT

Redditors Track Election Night: Must-Watch Threads For Trump Vs. Harris Showdown, Other Races

CervoMed GAAP EPS of -$0.27, revenue of $3.29M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
CervoMed (NASDAQ:<a href="https://investorplace.com/stock-quotes/crvo-stock-quote/">CRVO</a>) just reported results for the second quarter of 2024.<ul><li>CervoMed reported earnings per share of -27 cents. This was above the analyst estimate for EPS of -38 cents.</li><li>The company reported revenue of $3.29 million.</li><li>This was 49.50% better than the analyst estimate for revenue of $2.20 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/crvo-stock-earnings-cervomed-for-q2-of-2024/">CRVO Stock Earnings: CervoMed Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CRVO Stock Earnings: CervoMed Beats EPS, Beats Revenue for Q2 2024

CervoMed (CRVO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from JonesTradin...

CervoMed: A Strong Buy on Pioneering DLB Treatment and Solid Financial Footing

Morgan Stanley analyst Jeffrey Hung maintained a Buy rating on CervoMed (CRVO – Research Report) today and set a price target of $35.00. The compan...

Morgan Stanley Sticks to Their Buy Rating for CervoMed (CRVO)

CervoMed (CRVO) just unveiled an update. Cervomed has released key information about its business operations, clinical studies, and financial statu...

CervoMed Updates Investors on Business and Clinical Progress

Sumant Kulkarni, an analyst from Canaccord Genuity, maintained the Buy rating on CervoMed (CRVO – Research Report). The associated price target rem...

CervoMed's Neflamapimod Shows Promise in DLB: A Buy Rating with a $65 Price Target

The latest update is out from CervoMed ( ($CRVO) ). CervoMed Inc. had an agreement in place to sell up to $20 million of its common stock through B...

CervoMed Ends $20 Million Stock Sales Agreement with BTIG

CervoMed files for $250M mixed securities shelf

Analyst Sumant Kulkarni of Canaccord Genuity maintained a Buy rating on CervoMed (CRVO – Research Report), retaining the price target of $65.00. Su...

CervoMed's Neflamapimod: A Promising Phase 2b Trial for Addressing Dementia with Lewy Bodies

CervoMed (CRVO) announced key takeaways from two oral presentations characterizing the potential of neflamapimod as a treatment for patients with d...

CervoMed announces key takeaways from presentations on neflamapimod

CRVO

Health Care

Press Releases

CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Earnings

CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

CervoMed to Participate in Upcoming Investor Conferences

CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

Comments

CervoMed

CervoMed (CRVO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO